EUVIMEDEUVIMED entdecken
Crossref

Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT ‐ MMO trial

Carolyn S P Lam iD, Angel Rodriguez, Ali Aminian, Ele Ferrannini, Hiddo J L Heerspink, Ania M Jastreboff iD, Luke J Laffin, Ambarish Pandey, Kausik K Ray, Paul M Ridker, Arun J Sanyal, Hannele Yki-Jarvinen und 8 weitere

Obesity · 2025-09 · 33 (9) · 1645-1656

DOI: 10.1002/oby.24332 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesity, online erschienen am 22.06.2025. Verfasst von Carolyn S P Lam und 19 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular and Metabolic Disorders Programme, Duke-National University of Singapore Medical School, Singapore, Singapore. Hauptthemen laut MEDLINE: Obesity, Cardiovascular Diseases, Tirzepatide. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Obesity is a major cause of morbidity and mortality worldwide. Tirzepatide is a glucose‐dependent insulinotropic polypeptide receptor and glucagon‐like peptide‐1 receptor agonist providing substantial weight reduction and metabolic benefits both in type 2 diabetes and obesity. We hypothesized that tirzepatide can improve morbidity and mortality in adults with obesity or overweight but without diabetes.

Methods

SURMOUNT‐MMO is a randomized, double‐blind, event‐driven trial to investigate the impact on morbidity and mortality with once‐weekly tirzepatide compared with placebo in adults living with obesity, without diabetes, and with, or at risk of, cardiovascular disease. The primary endpoint is time to first occurrence of a five‐component composite outcome of nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, heart failure events, or death from any cause.

Results

The trial will enroll ~15,000 participants aged ≥40 from 664 sites across 27 countries with BMI ≥27.0 kg/m 2 and either established cardiovascular disease or multiple cardiovascular risk factors.

Conclusions

SURMOUNT‐MMO will provide evidence of the clinical benefits of tirzepatide on multiple outcomes among individuals with overweight or obesity but without diabetes. This is the first outcome trial of an incretin medication that assesses both primary and secondary cardiovascular disease prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityCardiovascular DiseasesTirzepatideHumansDouble-Blind MethodMaleFemaleMiddle AgedAdultRandomized Controlled Trials as TopicDiabetes Mellitus, Type 2OverweightAged

Substanzen

Tirzepatide

Autor:innen und Institutionen

  • Cardiovascular and Metabolic Disorders Programme, Duke-National University of Singapore Medical School, Singapore, Singapore.
  • National Heart Centre Singapore, Singapore, Singapore.
  • Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Bariatric and Metabolic Institute, Department of General Surgery, Cleveland Clinic, Cleveland, Ohio, USA.
  • Endocrinology and Metabolic Diseases, CNR Institute of Clinical Physiology, Pisa, Italy.
  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.

ORCID-Profile: Carolyn S P Lam, Ania M Jastreboff

Förderung

  • Eli Lilly and Company

Zitieren

APA

Lam, C. S. P., Rodriguez, A., Aminian, A., Ferrannini, E., Heerspink, H. J. L., Jastreboff, A. M., Laffin, L. J., Pandey, A., Ray, K. K., Ridker, P. M., Sanyal, A. J., Yki-Jarvinen, H., Mason, D., Strzelecki, M., Bartee, A. K., Cui, C., Hurt, K., Linetzky, B., Bunck, M. C., & Nissen, S. E. (2025). Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT ‐ MMO trial. Obesity, 33(9), 1645-1656. https://doi.org/10.1002/oby.24332

Vancouver

Lam CSP, Rodriguez A, Aminian A, Ferrannini E, Heerspink HJL, Jastreboff AM, et al. Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT ‐ MMO trial. Obesity. 2025;33(9):1645-1656. doi:10.1002/oby.24332

BibTeX
@article{Lam2025,
  author = {Lam, Carolyn S P and Rodriguez, Angel and Aminian, Ali and Ferrannini, Ele and Heerspink, Hiddo J L and Jastreboff, Ania M and Laffin, Luke J and Pandey, Ambarish and Ray, Kausik K and Ridker, Paul M and Sanyal, Arun J and Yki-Jarvinen, Hannele and Mason, Denise and Strzelecki, Michelle and Bartee, Amy K and Cui, Can and Hurt, Karla and Linetzky, Bruno and Bunck, Mathijs C and Nissen, Steven E},
  title = {Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT ‐ MMO trial},
  journal = {Obesity},
  year = {2025},
  volume = {33},
  number = {9},
  pages = {1645--1656},
  doi = {10.1002/oby.24332}
}
Kostenlos starten →